nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—PTGS2—lung cancer	0.551	1	CbGaD
Nepafenac—PTGS2—Cisplatin—lung cancer	0.0915	0.356	CbGbCtD
Nepafenac—PTGS2—Etoposide—lung cancer	0.0899	0.349	CbGbCtD
Nepafenac—PTGS1—Etoposide—lung cancer	0.0759	0.295	CbGbCtD
Nepafenac—Ulcerative keratitis—Erlotinib—lung cancer	0.00524	0.0422	CcSEcCtD
Nepafenac—Ocular hyperaemia—Gefitinib—lung cancer	0.00472	0.0381	CcSEcCtD
Nepafenac—Visual acuity reduced—Crizotinib—lung cancer	0.0041	0.033	CcSEcCtD
Nepafenac—Blepharitis—Gefitinib—lung cancer	0.0036	0.029	CcSEcCtD
Nepafenac—Keratitis—Gefitinib—lung cancer	0.00341	0.0275	CcSEcCtD
Nepafenac—Lacrimation increased—Pemetrexed—lung cancer	0.00242	0.0195	CcSEcCtD
Nepafenac—Photophobia—Crizotinib—lung cancer	0.00229	0.0185	CcSEcCtD
Nepafenac—Ocular discomfort—Methotrexate—lung cancer	0.00207	0.0167	CcSEcCtD
Nepafenac—Dry eye—Gefitinib—lung cancer	0.00205	0.0165	CcSEcCtD
Nepafenac—Keratitis—Erlotinib—lung cancer	0.00204	0.0165	CcSEcCtD
Nepafenac—Mefenamic acid—AKR1C1—lung cancer	0.00203	0.235	CrCbGaD
Nepafenac—Eye pain—Gefitinib—lung cancer	0.00178	0.0144	CcSEcCtD
Nepafenac—Eye pruritus—Paclitaxel—lung cancer	0.00172	0.0139	CcSEcCtD
Nepafenac—Lacrimation—Irinotecan—lung cancer	0.00161	0.0129	CcSEcCtD
Nepafenac—Visual acuity reduced—Paclitaxel—lung cancer	0.00129	0.0104	CcSEcCtD
Nepafenac—Photophobia—Vinblastine—lung cancer	0.00129	0.0104	CcSEcCtD
Nepafenac—Dermatitis atopic—Gemcitabine—lung cancer	0.00124	0.01	CcSEcCtD
Nepafenac—Dry eye—Erlotinib—lung cancer	0.00122	0.00985	CcSEcCtD
Nepafenac—Keratitis—Paclitaxel—lung cancer	0.00119	0.00957	CcSEcCtD
Nepafenac—Eye disorder—Crizotinib—lung cancer	0.00114	0.00922	CcSEcCtD
Nepafenac—Lacrimation—Docetaxel—lung cancer	0.00111	0.00894	CcSEcCtD
Nepafenac—Impaired healing—Methotrexate—lung cancer	0.00109	0.00877	CcSEcCtD
Nepafenac—Eye disorder—Pemetrexed—lung cancer	0.00105	0.00843	CcSEcCtD
Nepafenac—Dermatitis atopic—Paclitaxel—lung cancer	0.00104	0.00838	CcSEcCtD
Nepafenac—Eye disorder—Gefitinib—lung cancer	0.00104	0.00838	CcSEcCtD
Nepafenac—Lacrimation increased—Irinotecan—lung cancer	0.00102	0.00826	CcSEcCtD
Nepafenac—Angiopathy—Gefitinib—lung cancer	0.00101	0.00813	CcSEcCtD
Nepafenac—Vision blurred—Crizotinib—lung cancer	0.001	0.0081	CcSEcCtD
Nepafenac—Eye irritation—Paclitaxel—lung cancer	0.000901	0.00727	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Crizotinib—lung cancer	0.000901	0.00726	CcSEcCtD
Nepafenac—Dermatitis atopic—Docetaxel—lung cancer	0.000882	0.00711	CcSEcCtD
Nepafenac—Nervous system disorder—Crizotinib—lung cancer	0.000853	0.00688	CcSEcCtD
Nepafenac—Skin disorder—Crizotinib—lung cancer	0.000845	0.00681	CcSEcCtD
Nepafenac—Hypertension—Pemetrexed—lung cancer	0.000841	0.00678	CcSEcCtD
Nepafenac—Lacrimation increased—Paclitaxel—lung cancer	0.000835	0.00673	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Pemetrexed—lung cancer	0.000824	0.00664	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Gefitinib—lung cancer	0.000818	0.0066	CcSEcCtD
Nepafenac—Dry mouth—Gefitinib—lung cancer	0.000806	0.0065	CcSEcCtD
Nepafenac—Nervous system disorder—Pemetrexed—lung cancer	0.00078	0.00628	CcSEcCtD
Nepafenac—Nervous system disorder—Gefitinib—lung cancer	0.000775	0.00624	CcSEcCtD
Nepafenac—Skin disorder—Pemetrexed—lung cancer	0.000772	0.00622	CcSEcCtD
Nepafenac—Blood pressure increased—Paclitaxel—lung cancer	0.00077	0.00621	CcSEcCtD
Nepafenac—Skin disorder—Gefitinib—lung cancer	0.000767	0.00619	CcSEcCtD
Nepafenac—Eye irritation—Docetaxel—lung cancer	0.000764	0.00616	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Crizotinib—lung cancer	0.000751	0.00605	CcSEcCtD
Nepafenac—Dry eye—Paclitaxel—lung cancer	0.000711	0.00573	CcSEcCtD
Nepafenac—Lacrimation increased—Docetaxel—lung cancer	0.000708	0.00571	CcSEcCtD
Nepafenac—Lacrimation—Doxorubicin—lung cancer	0.000693	0.00558	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Pemetrexed—lung cancer	0.000686	0.00553	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Gefitinib—lung cancer	0.000682	0.0055	CcSEcCtD
Nepafenac—Hypertension—Teniposide—lung cancer	0.000681	0.00549	CcSEcCtD
Nepafenac—Blood pressure increased—Docetaxel—lung cancer	0.000652	0.00526	CcSEcCtD
Nepafenac—Keratitis—Doxorubicin—lung cancer	0.000628	0.00506	CcSEcCtD
Nepafenac—Eye disorder—Erlotinib—lung cancer	0.000621	0.00501	CcSEcCtD
Nepafenac—Eye pain—Paclitaxel—lung cancer	0.000619	0.00499	CcSEcCtD
Nepafenac—Angiopathy—Topotecan—lung cancer	0.00061	0.00491	CcSEcCtD
Nepafenac—Immune system disorder—Topotecan—lung cancer	0.000607	0.00489	CcSEcCtD
Nepafenac—Hypersensitivity—Pemetrexed—lung cancer	0.000586	0.00472	CcSEcCtD
Nepafenac—Hypersensitivity—Gefitinib—lung cancer	0.000582	0.00469	CcSEcCtD
Nepafenac—Dizziness—Crizotinib—lung cancer	0.000575	0.00464	CcSEcCtD
Nepafenac—Pruritus—Pemetrexed—lung cancer	0.000562	0.00453	CcSEcCtD
Nepafenac—Pruritus—Gefitinib—lung cancer	0.000559	0.00451	CcSEcCtD
Nepafenac—Vomiting—Crizotinib—lung cancer	0.000553	0.00446	CcSEcCtD
Nepafenac—Dermatitis atopic—Doxorubicin—lung cancer	0.00055	0.00443	CcSEcCtD
Nepafenac—Diclofenac—UGT1A1—lung cancer	0.00054	0.0624	CrCbGaD
Nepafenac—Dizziness—Pemetrexed—lung cancer	0.000526	0.00424	CcSEcCtD
Nepafenac—Angiopathy—Vinorelbine—lung cancer	0.000521	0.0042	CcSEcCtD
Nepafenac—Hypertension—Vinblastine—lung cancer	0.00052	0.00419	CcSEcCtD
Nepafenac—Immune system disorder—Vinorelbine—lung cancer	0.000519	0.00418	CcSEcCtD
Nepafenac—Nausea—Crizotinib—lung cancer	0.000517	0.00417	CcSEcCtD
Nepafenac—Diclofenac—CXCL8—lung cancer	0.000509	0.0588	CrCbGaD
Nepafenac—Vomiting—Pemetrexed—lung cancer	0.000505	0.00407	CcSEcCtD
Nepafenac—Vomiting—Gefitinib—lung cancer	0.000502	0.00405	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.000494	0.00399	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.000489	0.00394	CcSEcCtD
Nepafenac—Mebendazole—CYP1A1—lung cancer	0.000487	0.0562	CrCbGaD
Nepafenac—Hypersensitivity—Teniposide—lung cancer	0.000474	0.00382	CcSEcCtD
Nepafenac—Nausea—Pemetrexed—lung cancer	0.000472	0.00381	CcSEcCtD
Nepafenac—Nausea—Gefitinib—lung cancer	0.000469	0.00378	CcSEcCtD
Nepafenac—Nervous system disorder—Topotecan—lung cancer	0.000468	0.00377	CcSEcCtD
Nepafenac—Skin disorder—Topotecan—lung cancer	0.000464	0.00374	CcSEcCtD
Nepafenac—Nervous system disorder—Erlotinib—lung cancer	0.000463	0.00373	CcSEcCtD
Nepafenac—Skin disorder—Erlotinib—lung cancer	0.000459	0.0037	CcSEcCtD
Nepafenac—Pruritus—Teniposide—lung cancer	0.000456	0.00367	CcSEcCtD
Nepafenac—Ketoprofen—CXCL8—lung cancer	0.000451	0.0521	CrCbGaD
Nepafenac—Lacrimation increased—Doxorubicin—lung cancer	0.000442	0.00356	CcSEcCtD
Nepafenac—Hypertension—Vinorelbine—lung cancer	0.000432	0.00348	CcSEcCtD
Nepafenac—Angiopathy—Irinotecan—lung cancer	0.00043	0.00347	CcSEcCtD
Nepafenac—Immune system disorder—Irinotecan—lung cancer	0.000428	0.00345	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.000423	0.00341	CcSEcCtD
Nepafenac—Angiopathy—Gemcitabine—lung cancer	0.000419	0.00338	CcSEcCtD
Nepafenac—Ketorolac—PTGS2—lung cancer	0.000419	0.0484	CrCbGaD
Nepafenac—Immune system disorder—Gemcitabine—lung cancer	0.000417	0.00336	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Topotecan—lung cancer	0.000412	0.00332	CcSEcCtD
Nepafenac—Vomiting—Teniposide—lung cancer	0.000409	0.0033	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Erlotinib—lung cancer	0.000408	0.00329	CcSEcCtD
Nepafenac—Sinusitis—Paclitaxel—lung cancer	0.000404	0.00326	CcSEcCtD
Nepafenac—Headache—Teniposide—lung cancer	0.000403	0.00325	CcSEcCtD
Nepafenac—Eye disorder—Cisplatin—lung cancer	0.000402	0.00324	CcSEcCtD
Nepafenac—Bromfenac—PTGS2—lung cancer	0.000401	0.0464	CrCbGaD
Nepafenac—Nervous system disorder—Vinorelbine—lung cancer	0.0004	0.00323	CcSEcCtD
Nepafenac—Skin disorder—Vinorelbine—lung cancer	0.000397	0.0032	CcSEcCtD
Nepafenac—Diabetes mellitus—Methotrexate—lung cancer	0.000392	0.00316	CcSEcCtD
Nepafenac—Immune system disorder—Cisplatin—lung cancer	0.000389	0.00313	CcSEcCtD
Nepafenac—Nausea—Teniposide—lung cancer	0.000383	0.00308	CcSEcCtD
Nepafenac—Dry eye—Doxorubicin—lung cancer	0.000376	0.00303	CcSEcCtD
Nepafenac—Eye disorder—Etoposide—lung cancer	0.000368	0.00297	CcSEcCtD
Nepafenac—Hypersensitivity—Vinblastine—lung cancer	0.000362	0.00292	CcSEcCtD
Nepafenac—Eye disorder—Paclitaxel—lung cancer	0.000361	0.00291	CcSEcCtD
Nepafenac—Angiopathy—Etoposide—lung cancer	0.000358	0.00288	CcSEcCtD
Nepafenac—Hypertension—Irinotecan—lung cancer	0.000356	0.00287	CcSEcCtD
Nepafenac—Immune system disorder—Etoposide—lung cancer	0.000356	0.00287	CcSEcCtD
Nepafenac—Vision blurred—Cisplatin—lung cancer	0.000353	0.00285	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000353	0.00284	CcSEcCtD
Nepafenac—Hypersensitivity—Topotecan—lung cancer	0.000352	0.00283	CcSEcCtD
Nepafenac—Angiopathy—Paclitaxel—lung cancer	0.000351	0.00283	CcSEcCtD
Nepafenac—Immune system disorder—Paclitaxel—lung cancer	0.000349	0.00281	CcSEcCtD
Nepafenac—Hypertension—Gemcitabine—lung cancer	0.000347	0.0028	CcSEcCtD
Nepafenac—Tiaprofenic acid—PTGS2—lung cancer	0.000341	0.0394	CrCbGaD
Nepafenac—Diabetes mellitus—Doxorubicin—lung cancer	0.00034	0.00274	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.00034	0.00274	CcSEcCtD
Nepafenac—Pruritus—Topotecan—lung cancer	0.000338	0.00272	CcSEcCtD
Nepafenac—Pruritus—Erlotinib—lung cancer	0.000334	0.00269	CcSEcCtD
Nepafenac—Nervous system disorder—Irinotecan—lung cancer	0.00033	0.00266	CcSEcCtD
Nepafenac—Eye pain—Doxorubicin—lung cancer	0.000327	0.00264	CcSEcCtD
Nepafenac—Dizziness—Vinblastine—lung cancer	0.000325	0.00262	CcSEcCtD
Nepafenac—Nervous system disorder—Gemcitabine—lung cancer	0.000322	0.00259	CcSEcCtD
Nepafenac—Skin disorder—Gemcitabine—lung cancer	0.000319	0.00257	CcSEcCtD
Nepafenac—Magnesium salicylate—PTGS2—lung cancer	0.000317	0.0367	CrCbGaD
Nepafenac—Vision blurred—Paclitaxel—lung cancer	0.000317	0.00256	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000317	0.00255	CcSEcCtD
Nepafenac—Dizziness—Topotecan—lung cancer	0.000316	0.00254	CcSEcCtD
Nepafenac—Vomiting—Vinblastine—lung cancer	0.000312	0.00252	CcSEcCtD
Nepafenac—Dizziness—Erlotinib—lung cancer	0.000312	0.00252	CcSEcCtD
Nepafenac—Fenbufen—PTGS2—lung cancer	0.000311	0.0359	CrCbGaD
Nepafenac—Headache—Vinblastine—lung cancer	0.000308	0.00248	CcSEcCtD
Nepafenac—Eye disorder—Docetaxel—lung cancer	0.000306	0.00247	CcSEcCtD
Nepafenac—Vomiting—Topotecan—lung cancer	0.000303	0.00245	CcSEcCtD
Nepafenac—Hypersensitivity—Vinorelbine—lung cancer	0.000301	0.00242	CcSEcCtD
Nepafenac—Vomiting—Erlotinib—lung cancer	0.0003	0.00242	CcSEcCtD
Nepafenac—Nervous system disorder—Cisplatin—lung cancer	0.0003	0.00242	CcSEcCtD
Nepafenac—Headache—Topotecan—lung cancer	0.000299	0.00241	CcSEcCtD
Nepafenac—Angiopathy—Docetaxel—lung cancer	0.000297	0.0024	CcSEcCtD
Nepafenac—Skin disorder—Cisplatin—lung cancer	0.000297	0.00239	CcSEcCtD
Nepafenac—Hypertension—Etoposide—lung cancer	0.000296	0.00239	CcSEcCtD
Nepafenac—Immune system disorder—Docetaxel—lung cancer	0.000296	0.00239	CcSEcCtD
Nepafenac—Headache—Erlotinib—lung cancer	0.000296	0.00238	CcSEcCtD
Nepafenac—Nausea—Vinblastine—lung cancer	0.000292	0.00235	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Irinotecan—lung cancer	0.000291	0.00234	CcSEcCtD
Nepafenac—Hypertension—Paclitaxel—lung cancer	0.000291	0.00234	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00029	0.00234	CcSEcCtD
Nepafenac—Pruritus—Vinorelbine—lung cancer	0.000289	0.00233	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000285	0.00229	CcSEcCtD
Nepafenac—Nausea—Topotecan—lung cancer	0.000284	0.00229	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000283	0.00228	CcSEcCtD
Nepafenac—Magnesium salicylate—ALB—lung cancer	0.000283	0.0327	CrCbGaD
Nepafenac—Nausea—Erlotinib—lung cancer	0.000281	0.00226	CcSEcCtD
Nepafenac—Dry mouth—Paclitaxel—lung cancer	0.00028	0.00226	CcSEcCtD
Nepafenac—Skin disorder—Etoposide—lung cancer	0.000272	0.00219	CcSEcCtD
Nepafenac—Dizziness—Vinorelbine—lung cancer	0.00027	0.00218	CcSEcCtD
Nepafenac—Salsalate—PTGS2—lung cancer	0.00027	0.0312	CrCbGaD
Nepafenac—Nervous system disorder—Paclitaxel—lung cancer	0.000269	0.00217	CcSEcCtD
Nepafenac—Skin disorder—Paclitaxel—lung cancer	0.000267	0.00215	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Cisplatin—lung cancer	0.000264	0.00213	CcSEcCtD
Nepafenac—Vomiting—Vinorelbine—lung cancer	0.00026	0.00209	CcSEcCtD
Nepafenac—Mebendazole—ABCB1—lung cancer	0.000259	0.0299	CrCbGaD
Nepafenac—Headache—Vinorelbine—lung cancer	0.000256	0.00206	CcSEcCtD
Nepafenac—Hypersensitivity—Irinotecan—lung cancer	0.000248	0.002	CcSEcCtD
Nepafenac—Hypertension—Docetaxel—lung cancer	0.000246	0.00199	CcSEcCtD
Nepafenac—Nausea—Vinorelbine—lung cancer	0.000243	0.00196	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Etoposide—lung cancer	0.000242	0.00195	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000241	0.00194	CcSEcCtD
Nepafenac—Diclofenac—CYP2E1—lung cancer	0.000241	0.0278	CrCbGaD
Nepafenac—Diclofenac—CYP1A1—lung cancer	0.000238	0.0275	CrCbGaD
Nepafenac—Dry mouth—Docetaxel—lung cancer	0.000237	0.00191	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000237	0.00191	CcSEcCtD
Nepafenac—Pruritus—Gemcitabine—lung cancer	0.000232	0.00187	CcSEcCtD
Nepafenac—Nervous system disorder—Docetaxel—lung cancer	0.000228	0.00184	CcSEcCtD
Nepafenac—Skin disorder—Docetaxel—lung cancer	0.000226	0.00182	CcSEcCtD
Nepafenac—Hypersensitivity—Cisplatin—lung cancer	0.000225	0.00182	CcSEcCtD
Nepafenac—Fenoprofen—PTGS2—lung cancer	0.000223	0.0258	CrCbGaD
Nepafenac—Dizziness—Irinotecan—lung cancer	0.000223	0.0018	CcSEcCtD
Nepafenac—Eye disorder—Methotrexate—lung cancer	0.000221	0.00178	CcSEcCtD
Nepafenac—Angiopathy—Methotrexate—lung cancer	0.000214	0.00173	CcSEcCtD
Nepafenac—Vomiting—Irinotecan—lung cancer	0.000214	0.00173	CcSEcCtD
Nepafenac—Sinusitis—Doxorubicin—lung cancer	0.000214	0.00172	CcSEcCtD
Nepafenac—Immune system disorder—Methotrexate—lung cancer	0.000213	0.00172	CcSEcCtD
Nepafenac—Headache—Irinotecan—lung cancer	0.000211	0.0017	CcSEcCtD
Nepafenac—Vomiting—Gemcitabine—lung cancer	0.000209	0.00168	CcSEcCtD
Nepafenac—Mefenamic acid—PTGS2—lung cancer	0.000207	0.0239	CrCbGaD
Nepafenac—Hypersensitivity—Etoposide—lung cancer	0.000206	0.00166	CcSEcCtD
Nepafenac—Headache—Gemcitabine—lung cancer	0.000205	0.00166	CcSEcCtD
Nepafenac—Hypersensitivity—Paclitaxel—lung cancer	0.000202	0.00163	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Docetaxel—lung cancer	0.000201	0.00162	CcSEcCtD
Nepafenac—Nausea—Irinotecan—lung cancer	0.0002	0.00161	CcSEcCtD
Nepafenac—Fenoprofen—ALB—lung cancer	0.000199	0.0229	CrCbGaD
Nepafenac—Pruritus—Etoposide—lung cancer	0.000198	0.0016	CcSEcCtD
Nepafenac—Nausea—Gemcitabine—lung cancer	0.000195	0.00157	CcSEcCtD
Nepafenac—Vomiting—Cisplatin—lung cancer	0.000194	0.00157	CcSEcCtD
Nepafenac—Pruritus—Paclitaxel—lung cancer	0.000194	0.00157	CcSEcCtD
Nepafenac—Vision blurred—Methotrexate—lung cancer	0.000194	0.00156	CcSEcCtD
Nepafenac—Eye disorder—Doxorubicin—lung cancer	0.000191	0.00154	CcSEcCtD
Nepafenac—Angiopathy—Doxorubicin—lung cancer	0.000186	0.0015	CcSEcCtD
Nepafenac—Dizziness—Etoposide—lung cancer	0.000185	0.00149	CcSEcCtD
Nepafenac—Immune system disorder—Doxorubicin—lung cancer	0.000185	0.00149	CcSEcCtD
Nepafenac—Dizziness—Paclitaxel—lung cancer	0.000182	0.00146	CcSEcCtD
Nepafenac—Nausea—Cisplatin—lung cancer	0.000182	0.00146	CcSEcCtD
Nepafenac—Vomiting—Etoposide—lung cancer	0.000178	0.00144	CcSEcCtD
Nepafenac—Headache—Etoposide—lung cancer	0.000175	0.00141	CcSEcCtD
Nepafenac—Vomiting—Paclitaxel—lung cancer	0.000175	0.00141	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000174	0.0014	CcSEcCtD
Nepafenac—Headache—Paclitaxel—lung cancer	0.000172	0.00139	CcSEcCtD
Nepafenac—Hypersensitivity—Docetaxel—lung cancer	0.000172	0.00138	CcSEcCtD
Nepafenac—Vision blurred—Doxorubicin—lung cancer	0.000168	0.00135	CcSEcCtD
Nepafenac—Oxcarbazepine—ALB—lung cancer	0.000167	0.0192	CrCbGaD
Nepafenac—Nausea—Etoposide—lung cancer	0.000166	0.00134	CcSEcCtD
Nepafenac—Pruritus—Docetaxel—lung cancer	0.000165	0.00133	CcSEcCtD
Nepafenac—Nervous system disorder—Methotrexate—lung cancer	0.000165	0.00133	CcSEcCtD
Nepafenac—Nausea—Paclitaxel—lung cancer	0.000163	0.00132	CcSEcCtD
Nepafenac—Skin disorder—Methotrexate—lung cancer	0.000163	0.00131	CcSEcCtD
Nepafenac—Dizziness—Docetaxel—lung cancer	0.000154	0.00124	CcSEcCtD
Nepafenac—Hypertension—Doxorubicin—lung cancer	0.000154	0.00124	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000151	0.00121	CcSEcCtD
Nepafenac—Diclofenac—PTGS2—lung cancer	0.000149	0.0172	CrCbGaD
Nepafenac—Dry mouth—Doxorubicin—lung cancer	0.000148	0.00119	CcSEcCtD
Nepafenac—Vomiting—Docetaxel—lung cancer	0.000148	0.00119	CcSEcCtD
Nepafenac—Headache—Docetaxel—lung cancer	0.000146	0.00118	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Methotrexate—lung cancer	0.000145	0.00117	CcSEcCtD
Nepafenac—Nervous system disorder—Doxorubicin—lung cancer	0.000142	0.00115	CcSEcCtD
Nepafenac—Skin disorder—Doxorubicin—lung cancer	0.000141	0.00114	CcSEcCtD
Nepafenac—Nausea—Docetaxel—lung cancer	0.000138	0.00111	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—MYC—lung cancer	0.000136	0.00229	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—EGFR—lung cancer	0.000133	0.00224	CbGpPWpGaD
Nepafenac—Diclofenac—ALB—lung cancer	0.000132	0.0153	CrCbGaD
Nepafenac—Ketoprofen—PTGS2—lung cancer	0.000132	0.0152	CrCbGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	0.000128	0.00216	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—ALB—lung cancer	0.000127	0.00215	CbGpPWpGaD
Nepafenac—Diclofenac—ABCB1—lung cancer	0.000126	0.0146	CrCbGaD
Nepafenac—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000125	0.00101	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—KRAS—lung cancer	0.000125	0.00212	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—lung cancer	0.000125	0.00211	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—CDKN2A—lung cancer	0.000124	0.00209	CbGpPWpGaD
Nepafenac—Hypersensitivity—Methotrexate—lung cancer	0.000124	0.000996	CcSEcCtD
Nepafenac—PTGS1—Metabolism—COL4A3BP—lung cancer	0.000121	0.00205	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—AZIN2—lung cancer	0.000121	0.00205	CbGpPWpGaD
Nepafenac—Pruritus—Methotrexate—lung cancer	0.000119	0.000957	CcSEcCtD
Nepafenac—Ketoprofen—ALB—lung cancer	0.000117	0.0135	CrCbGaD
Nepafenac—PTGS2—C-MYB transcription factor network—CD4—lung cancer	0.000116	0.00197	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	0.000113	0.00191	CbGpPWpGaD
Nepafenac—Dizziness—Methotrexate—lung cancer	0.000111	0.000894	CcSEcCtD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	0.00011	0.00185	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—lung cancer	0.00011	0.00185	CbGpPWpGaD
Nepafenac—Carbamazepine—ABCB1—lung cancer	0.000108	0.0125	CrCbGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—lung cancer	0.000108	0.00182	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—RB1—lung cancer	0.000107	0.00181	CbGpPWpGaD
Nepafenac—Hypersensitivity—Doxorubicin—lung cancer	0.000107	0.000863	CcSEcCtD
Nepafenac—Vomiting—Methotrexate—lung cancer	0.000107	0.00086	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—HRAS—lung cancer	0.000107	0.0018	CbGpPWpGaD
Nepafenac—Headache—Methotrexate—lung cancer	0.000105	0.000847	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CCND1—lung cancer	0.000104	0.00177	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ATP5H—lung cancer	0.000103	0.00174	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—POMC—lung cancer	0.000103	0.00174	CbGpPWpGaD
Nepafenac—Pruritus—Doxorubicin—lung cancer	0.000103	0.000829	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CDKN1A—lung cancer	0.000101	0.00171	CbGpPWpGaD
Nepafenac—Nausea—Methotrexate—lung cancer	9.97e-05	0.000803	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—lung cancer	9.88e-05	0.00167	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—COL4A3BP—lung cancer	9.64e-05	0.00163	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—AZIN2—lung cancer	9.64e-05	0.00163	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—EP300—lung cancer	9.62e-05	0.00162	CbGpPWpGaD
Nepafenac—Dizziness—Doxorubicin—lung cancer	9.61e-05	0.000774	CcSEcCtD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	9.49e-05	0.0016	CbGpPWpGaD
Nepafenac—Vomiting—Doxorubicin—lung cancer	9.24e-05	0.000745	CcSEcCtD
Nepafenac—PTGS1—Metabolism—PLBD1—lung cancer	9.2e-05	0.00155	CbGpPWpGaD
Nepafenac—Headache—Doxorubicin—lung cancer	9.1e-05	0.000734	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—FGFR1—lung cancer	9.1e-05	0.00154	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	9.05e-05	0.00153	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—NRAS—lung cancer	9e-05	0.00152	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	8.99e-05	0.00152	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	8.71e-05	0.00147	CbGpPWpGaD
Nepafenac—Nausea—Doxorubicin—lung cancer	8.63e-05	0.000696	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—CXCL8—lung cancer	8.55e-05	0.00144	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—HSD17B10—lung cancer	8.42e-05	0.00142	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—MYC—lung cancer	8.38e-05	0.00142	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ATP5H—lung cancer	8.2e-05	0.00138	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CASP3—lung cancer	8.18e-05	0.00138	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL2—lung cancer	8.17e-05	0.00138	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CCND1—lung cancer	7.96e-05	0.00135	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—APC—lung cancer	7.9e-05	0.00133	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CKB—lung cancer	7.83e-05	0.00132	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—lung cancer	7.8e-05	0.00132	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—KRAS—lung cancer	7.74e-05	0.00131	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MMP9—lung cancer	7.73e-05	0.00131	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—IL6—lung cancer	7.65e-05	0.00129	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	7.53e-05	0.00127	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CNDP2—lung cancer	7.36e-05	0.00124	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTM2—lung cancer	7.36e-05	0.00124	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—lung cancer	7.35e-05	0.00124	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—lung cancer	7.32e-05	0.00124	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PLBD1—lung cancer	7.31e-05	0.00123	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	7.19e-05	0.00121	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—MTMR3—lung cancer	7.16e-05	0.00121	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MAP2K1—lung cancer	6.99e-05	0.00118	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PGAM1—lung cancer	6.98e-05	0.00118	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—HSD17B10—lung cancer	6.68e-05	0.00113	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP2A7—lung cancer	6.65e-05	0.00112	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PGAM1—lung cancer	6.61e-05	0.00112	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—HRAS—lung cancer	6.58e-05	0.00111	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MAPK3—lung cancer	6.57e-05	0.00111	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SDC4—lung cancer	6.51e-05	0.0011	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MYC—lung cancer	6.39e-05	0.00108	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—EGFR—lung cancer	6.25e-05	0.00106	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—lung cancer	6.22e-05	0.00105	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CKB—lung cancer	6.21e-05	0.00105	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—lung cancer	6.2e-05	0.00105	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SDC4—lung cancer	6.17e-05	0.00104	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—lung cancer	6.13e-05	0.00104	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—IL6—lung cancer	6.07e-05	0.00103	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—RRM1—lung cancer	5.93e-05	0.001	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTA3—lung cancer	5.93e-05	0.001	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTM2—lung cancer	5.84e-05	0.000987	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CNDP2—lung cancer	5.84e-05	0.000987	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—MTMR3—lung cancer	5.68e-05	0.00096	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—B4GALT5—lung cancer	5.58e-05	0.000942	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—lung cancer	5.56e-05	0.00094	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PGAM1—lung cancer	5.54e-05	0.000935	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SKI—lung cancer	5.45e-05	0.00092	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTA4—lung cancer	5.42e-05	0.000916	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—lung cancer	5.42e-05	0.000915	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—lung cancer	5.4e-05	0.000913	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	5.3e-05	0.000896	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTA2—lung cancer	5.29e-05	0.000893	CbGpPWpGaD
Nepafenac—PTGS2—Disease—B4GALT5—lung cancer	5.29e-05	0.000893	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP2A7—lung cancer	5.28e-05	0.000892	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TP53—lung cancer	5.24e-05	0.000886	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—lung cancer	5.24e-05	0.000885	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—lung cancer	5.23e-05	0.000883	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SDC4—lung cancer	5.17e-05	0.000873	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTA1—lung cancer	5.1e-05	0.000862	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ABCC3—lung cancer	5.04e-05	0.000852	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	4.99e-05	0.000842	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—AKR1C1—lung cancer	4.88e-05	0.000825	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	4.85e-05	0.000819	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL6—lung cancer	4.8e-05	0.000811	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—UGT1A1—lung cancer	4.74e-05	0.000801	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PXN—lung cancer	4.73e-05	0.000799	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	4.72e-05	0.000798	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—RRM1—lung cancer	4.71e-05	0.000795	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTA3—lung cancer	4.71e-05	0.000795	CbGpPWpGaD
Nepafenac—PTGS2—Disease—AKR1C1—lung cancer	4.63e-05	0.000782	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GNG11—lung cancer	4.57e-05	0.000772	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—APOA1—lung cancer	4.55e-05	0.000768	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	4.47e-05	0.000755	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—B4GALT5—lung cancer	4.43e-05	0.000748	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ALDOA—lung cancer	4.35e-05	0.000735	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	4.34e-05	0.000734	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTA4—lung cancer	4.31e-05	0.000728	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NPPA—lung cancer	4.26e-05	0.00072	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	4.25e-05	0.000718	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NCOA3—lung cancer	4.23e-05	0.000714	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	4.21e-05	0.000711	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTA2—lung cancer	4.2e-05	0.000709	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PPIA—lung cancer	4.16e-05	0.000703	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	4.15e-05	0.000702	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ALDOA—lung cancer	4.13e-05	0.000697	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ABCG2—lung cancer	4.11e-05	0.000695	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ADCY1—lung cancer	4.11e-05	0.000695	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTA1—lung cancer	4.05e-05	0.000684	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ENO2—lung cancer	4.03e-05	0.000681	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—HPGDS—lung cancer	4.03e-05	0.000681	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	4.01e-05	0.000678	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PPP2R1B—lung cancer	4.01e-05	0.000677	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ABCC3—lung cancer	4e-05	0.000676	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.95e-05	0.000668	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTT1—lung cancer	3.91e-05	0.000661	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ADCY1—lung cancer	3.9e-05	0.000658	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—AKR1C1—lung cancer	3.88e-05	0.000655	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP2A6—lung cancer	3.87e-05	0.000653	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GCLC—lung cancer	3.87e-05	0.000653	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.85e-05	0.00065	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ENO2—lung cancer	3.82e-05	0.000646	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PPP2R1B—lung cancer	3.8e-05	0.000642	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SMARCA4—lung cancer	3.8e-05	0.000642	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—UGT1A1—lung cancer	3.76e-05	0.000636	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	3.69e-05	0.000623	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ENO1—lung cancer	3.66e-05	0.000619	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.65e-05	0.000617	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GNG11—lung cancer	3.63e-05	0.000613	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	3.61e-05	0.00061	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.6e-05	0.000609	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	3.57e-05	0.000603	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ENO1—lung cancer	3.47e-05	0.000587	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ALDOA—lung cancer	3.46e-05	0.000584	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NCOA3—lung cancer	3.35e-05	0.000567	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	3.3e-05	0.000557	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP2E1—lung cancer	3.29e-05	0.000555	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ADCY1—lung cancer	3.26e-05	0.000551	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ABCG2—lung cancer	3.26e-05	0.000551	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NQO1—lung cancer	3.25e-05	0.000549	CbGpPWpGaD
Nepafenac—PTGS2—Disease—APP—lung cancer	3.23e-05	0.000546	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGF9—lung cancer	3.2e-05	0.000541	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ENO2—lung cancer	3.2e-05	0.000541	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—HPGDS—lung cancer	3.2e-05	0.000541	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.18e-05	0.000538	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PPP2R1B—lung cancer	3.18e-05	0.000537	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.15e-05	0.000533	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.14e-05	0.00053	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTT1—lung cancer	3.1e-05	0.000524	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GCLC—lung cancer	3.07e-05	0.000518	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP2A6—lung cancer	3.07e-05	0.000518	CbGpPWpGaD
Nepafenac—PTGS2—Disease—JUNB—lung cancer	3.06e-05	0.000517	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.06e-05	0.000516	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	3.01e-05	0.000509	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—STK11—lung cancer	2.93e-05	0.000495	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ENO1—lung cancer	2.91e-05	0.000491	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.9e-05	0.00049	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.86e-05	0.000483	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.75e-05	0.000465	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTP1—lung cancer	2.71e-05	0.000458	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FOXO3—lung cancer	2.68e-05	0.000453	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CAT—lung cancer	2.64e-05	0.000446	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.62e-05	0.000443	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP2E1—lung cancer	2.61e-05	0.000441	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NQO1—lung cancer	2.58e-05	0.000436	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ABCB1—lung cancer	2.57e-05	0.000433	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.53e-05	0.000427	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—TYMS—lung cancer	2.52e-05	0.000426	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTM1—lung cancer	2.49e-05	0.000421	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HES1—lung cancer	2.37e-05	0.000401	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP1A1—lung cancer	2.36e-05	0.000399	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ERCC2—lung cancer	2.34e-05	0.000396	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—STK11—lung cancer	2.33e-05	0.000393	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERCC2—lung cancer	2.22e-05	0.000375	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.18e-05	0.000369	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERBB3—lung cancer	2.17e-05	0.000367	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTP1—lung cancer	2.15e-05	0.000364	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CAT—lung cancer	2.09e-05	0.000354	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.08e-05	0.000352	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TERT—lung cancer	2.08e-05	0.000352	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ABCB1—lung cancer	2.04e-05	0.000344	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—APOA1—lung cancer	2.03e-05	0.000342	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGFR1—lung cancer	2.02e-05	0.000341	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TYMS—lung cancer	2e-05	0.000338	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HIF1A—lung cancer	1.99e-05	0.000336	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTM1—lung cancer	1.98e-05	0.000334	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.94e-05	0.000328	CbGpPWpGaD
Nepafenac—PTGS2—Disease—APOA1—lung cancer	1.92e-05	0.000324	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP1A1—lung cancer	1.87e-05	0.000317	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ERCC2—lung cancer	1.86e-05	0.000314	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CG—lung cancer	1.85e-05	0.000312	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—POMC—lung cancer	1.76e-05	0.000297	CbGpPWpGaD
Nepafenac—PTGS2—Disease—KIT—lung cancer	1.75e-05	0.000296	CbGpPWpGaD
Nepafenac—PTGS2—Disease—APC—lung cancer	1.75e-05	0.000296	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EGF—lung cancer	1.73e-05	0.000293	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CREBBP—lung cancer	1.71e-05	0.00029	CbGpPWpGaD
Nepafenac—PTGS2—Disease—BRAF—lung cancer	1.65e-05	0.000278	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IL6R—lung cancer	1.63e-05	0.000275	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CD—lung cancer	1.63e-05	0.000275	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CREBBP—lung cancer	1.63e-05	0.000275	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—APOA1—lung cancer	1.61e-05	0.000272	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ALB—lung cancer	1.61e-05	0.000271	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MAP2K1—lung cancer	1.55e-05	0.000262	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PIK3CD—lung cancer	1.54e-05	0.00026	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.54e-05	0.00026	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CG—lung cancer	1.47e-05	0.000248	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CB—lung cancer	1.42e-05	0.000239	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTGS2—lung cancer	1.4e-05	0.000237	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—POMC—lung cancer	1.4e-05	0.000236	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MDM2—lung cancer	1.38e-05	0.000233	CbGpPWpGaD
Nepafenac—PTGS2—Disease—RAF1—lung cancer	1.38e-05	0.000232	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CREBBP—lung cancer	1.36e-05	0.00023	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERBB2—lung cancer	1.36e-05	0.00023	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PIK3CB—lung cancer	1.34e-05	0.000227	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MTOR—lung cancer	1.34e-05	0.000227	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CD4—lung cancer	1.34e-05	0.000227	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CD—lung cancer	1.29e-05	0.000218	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ALB—lung cancer	1.27e-05	0.000215	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTEN—lung cancer	1.22e-05	0.000207	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—EP300—lung cancer	1.17e-05	0.000197	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CDKN1A—lung cancer	1.16e-05	0.000197	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PTEN—lung cancer	1.16e-05	0.000196	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CB—lung cancer	1.13e-05	0.00019	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EP300—lung cancer	1.11e-05	0.000187	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SRC—lung cancer	1.08e-05	0.000182	CbGpPWpGaD
Nepafenac—PTGS2—Disease—STAT3—lung cancer	1.04e-05	0.000175	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NRAS—lung cancer	1.04e-05	0.000175	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MAPK3—lung cancer	9.92e-06	0.000168	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PTEN—lung cancer	9.72e-06	0.000164	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MYC—lung cancer	9.65e-06	0.000163	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EGFR—lung cancer	9.44e-06	0.000159	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—EP300—lung cancer	9.27e-06	0.000157	CbGpPWpGaD
Nepafenac—PTGS2—Disease—KRAS—lung cancer	8.91e-06	0.000151	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CA—lung cancer	8.64e-06	0.000146	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PIK3CA—lung cancer	8.19e-06	0.000138	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HRAS—lung cancer	7.58e-06	0.000128	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IL6—lung cancer	7.25e-06	0.000123	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—AKT1—lung cancer	7.06e-06	0.000119	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CA—lung cancer	6.86e-06	0.000116	CbGpPWpGaD
Nepafenac—PTGS2—Disease—AKT1—lung cancer	6.69e-06	0.000113	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—AKT1—lung cancer	5.6e-06	9.46e-05	CbGpPWpGaD
